Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287524213> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4287524213 abstract "Gastric cancer (GC) patients with Epstein-Barr virus (EBV) positivity have demonstrated promising response with immunotherapy. We assessed the efficacy and safety of camrelizumab as salvage treatment in EBV-positive mGC. In this single-arm, phase 2 prospective clinical trial (NCT03755440), stage IV EBV-positive GC patients who failed/could not tolerate previous lines of chemotherapy were given intravenous camrelizumab 200 mg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was objective response rate. Secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response, and toxicity. Exploratory analysis included the associations between treatment response and tumor mutation burden (TMB), programmed cell death ligand-1 (PD-L1) expression. Six eligible patients were enrolled in the first stage of the study. No patient achieved an objective response; thus, the study did not proceed to the second stage. The DCR was 67% (4/6). The median PFS rate was 2.2 months (95% CI: 1.5-not reached [NR]) and median OS was 6.8 months (95% CI: 1.7-NR). All treatment-related adverse events were grade 1-2, with reactive cutaneous capillary endothelial proliferation (n=4 [67%]) being the most commonly observed event. The only patient with PD-L1 combined positive score >1 had disease progression. Two stable disease and one disease progression were observed in three patients with TMB >10 Mut/Mb. EBV positivity may not be a good predictor for response to camrelizumab in mGC. Newer biomarkers are needed to identify EBV-positive mGC respondents who might benefit from immunotherapy." @default.
- W4287524213 created "2022-07-25" @default.
- W4287524213 creator A5001864411 @default.
- W4287524213 creator A5006827480 @default.
- W4287524213 creator A5015096848 @default.
- W4287524213 creator A5015184109 @default.
- W4287524213 creator A5025489995 @default.
- W4287524213 creator A5040257073 @default.
- W4287524213 creator A5054320083 @default.
- W4287524213 creator A5084067884 @default.
- W4287524213 creator A5084421656 @default.
- W4287524213 creator A5085435487 @default.
- W4287524213 creator A5088993431 @default.
- W4287524213 creator A5090177646 @default.
- W4287524213 date "2021-01-01" @default.
- W4287524213 modified "2023-10-17" @default.
- W4287524213 title "PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial." @default.
- W4287524213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34765307" @default.
- W4287524213 hasPublicationYear "2021" @default.
- W4287524213 type Work @default.
- W4287524213 citedByCount "6" @default.
- W4287524213 countsByYear W42875242132022 @default.
- W4287524213 countsByYear W42875242132023 @default.
- W4287524213 crossrefType "journal-article" @default.
- W4287524213 hasAuthorship W4287524213A5001864411 @default.
- W4287524213 hasAuthorship W4287524213A5006827480 @default.
- W4287524213 hasAuthorship W4287524213A5015096848 @default.
- W4287524213 hasAuthorship W4287524213A5015184109 @default.
- W4287524213 hasAuthorship W4287524213A5025489995 @default.
- W4287524213 hasAuthorship W4287524213A5040257073 @default.
- W4287524213 hasAuthorship W4287524213A5054320083 @default.
- W4287524213 hasAuthorship W4287524213A5084067884 @default.
- W4287524213 hasAuthorship W4287524213A5084421656 @default.
- W4287524213 hasAuthorship W4287524213A5085435487 @default.
- W4287524213 hasAuthorship W4287524213A5088993431 @default.
- W4287524213 hasAuthorship W4287524213A5090177646 @default.
- W4287524213 hasConcept C121608353 @default.
- W4287524213 hasConcept C126322002 @default.
- W4287524213 hasConcept C143998085 @default.
- W4287524213 hasConcept C197934379 @default.
- W4287524213 hasConcept C203014093 @default.
- W4287524213 hasConcept C203092338 @default.
- W4287524213 hasConcept C2776694085 @default.
- W4287524213 hasConcept C2777701055 @default.
- W4287524213 hasConcept C2778822529 @default.
- W4287524213 hasConcept C2779984678 @default.
- W4287524213 hasConcept C2780739268 @default.
- W4287524213 hasConcept C31760486 @default.
- W4287524213 hasConcept C535046627 @default.
- W4287524213 hasConcept C71924100 @default.
- W4287524213 hasConcept C90924648 @default.
- W4287524213 hasConceptScore W4287524213C121608353 @default.
- W4287524213 hasConceptScore W4287524213C126322002 @default.
- W4287524213 hasConceptScore W4287524213C143998085 @default.
- W4287524213 hasConceptScore W4287524213C197934379 @default.
- W4287524213 hasConceptScore W4287524213C203014093 @default.
- W4287524213 hasConceptScore W4287524213C203092338 @default.
- W4287524213 hasConceptScore W4287524213C2776694085 @default.
- W4287524213 hasConceptScore W4287524213C2777701055 @default.
- W4287524213 hasConceptScore W4287524213C2778822529 @default.
- W4287524213 hasConceptScore W4287524213C2779984678 @default.
- W4287524213 hasConceptScore W4287524213C2780739268 @default.
- W4287524213 hasConceptScore W4287524213C31760486 @default.
- W4287524213 hasConceptScore W4287524213C535046627 @default.
- W4287524213 hasConceptScore W4287524213C71924100 @default.
- W4287524213 hasConceptScore W4287524213C90924648 @default.
- W4287524213 hasLocation W42875242131 @default.
- W4287524213 hasOpenAccess W4287524213 @default.
- W4287524213 hasPrimaryLocation W42875242131 @default.
- W4287524213 hasRelatedWork W12229326 @default.
- W4287524213 hasRelatedWork W13474352 @default.
- W4287524213 hasRelatedWork W17437393 @default.
- W4287524213 hasRelatedWork W19039903 @default.
- W4287524213 hasRelatedWork W19072084 @default.
- W4287524213 hasRelatedWork W19887974 @default.
- W4287524213 hasRelatedWork W20286704 @default.
- W4287524213 hasRelatedWork W2065971 @default.
- W4287524213 hasRelatedWork W3521414 @default.
- W4287524213 hasRelatedWork W18345989 @default.
- W4287524213 isParatext "false" @default.
- W4287524213 isRetracted "false" @default.
- W4287524213 workType "article" @default.